中生製藥(01177.HK)贖回2025年到期可轉換債券 涉4.9億歐元
中生製藥(01177.HK)公布,有關公司所發行7.5億歐元2025年到期的零息可轉換債券,於今年1月17日,要求公司贖回本金總額約4.88億歐元債券的可選認沽行權通知已送達公司支付代理,被贖回債券佔於目前該債券未償還本金額約99.6%。緊隨贖回被贖回債券完成後,債券仍未償還本金額將為215萬歐元。
贖回金額將由內部資源撥付。集團指一直維持充裕的流動資金,於去年底的現金及銀行結餘超過約110億元人民幣,足以應付有關贖回被贖回債券的所有資金需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.